Research Article| Volume 20, SUPPLEMENT 3, C32-C39, 1998

Postmarketing drug surveillance: an epidemiologic approach

  • Sean Hennessy
    Address correspondence to: Sean Hennessy, PharmD, MSCE, 803 Blockley Hall, University of Pennsylvania, Philadelphia, PA 19104-6021.
    Department of Biostatistics & Epidemiology, and Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Postmarketing surveillance refers to any means of gathering information about a product after it has been approved for public use. Postmarketing surveillance studies address assorted aspects of beneficial and detrimental adverse drug effects, including the existence of particular causal effects, frequency of and risk factors for certain outcomes, economic consequences of therapy, and characterization of drug use in clinical practice. The primary scientific discipline engaged in postmarketing studies is epidemiology. The principal epidemiologic study designs used in postmarketing surveillance studies are randomized trials, cohort studies, and case-control studies. Regardless of their design, all studies involving human subjects should be conducted by qualified investigators according to a written protocol that has been approved by an institutional review board. Promotional activities conducted under the guise of postmarketing studies are unacceptable.



        • Fassihi AR
        • Robertson SS
        Post-marketing drug surveillance—concepts, insights and applications.
        S Afr Med J. 1990; 77: 577-580
        • Massarotti M
        • Matano AM
        Problems of drug surveillance—An international view.
        Acta Neurochir Suppl. 1990; 50: 26-31
        • Ray WA
        • Griffin MR
        • Avorn J
        Evaluating drugs after their approval for clinical use.
        NEJM. 1993; 329: 2029-2032
        • Schafer H
        Post-approval drug research: Objectives and methods.
        Pharmacopsychiatry. 1997; 30: 4-8
        • Strom BL
        What is pharmacoepidemiology?.
        in: Strom BL 2nd ed. Pharmacoepidemiology. John Wiley, Chester1994: 3-13
      1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
        NEJM. 1991; 325: 293-302
        • Fischl MA
        • Dickinson GM
        • La Voie L
        Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.
        JAMA. 1988; 259: 1185-1189
        • Ray WA
        • Griffin MR
        • Downey W
        • Melton III, LJ
        Long-term use of thiazide diuretics and risk of hip fracture.
        Lancet. 1989; 1: 687-690
        • Felson DT
        • Sloutskis D
        • Anderson JJ
        • et al.
        Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study.
        JAMA. 1991; 265: 370-373
        • LaCroix AZ
        • Wienpahl J
        • White LR
        • et al.
        Thiazide diuretic agents and the incidence of hip fracture.
        NEJM. 1990; 322: 286-290
        • Herings RM
        • Stricker BH
        • de Boer A
        • et al.
        Current use of thiazide diuretics and prevention of femur fractures.
        J Clin Epidemiol. 1996; 49: 115-119
        • Hurwitz ES
        • Barrett MJ
        • Bregman D
        • et al.
        Public Health Service study on Reye's syndrome and medications.
        NEJM. 1985; 313 (Report of the pilot phase): 849-857
      2. CAST Investigators. Preliminary report: Effect of enaainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
        NEJM. 1989; 321: 406-412
        • Thapa PB
        • Gideon P
        • Fought RL
        • Ray WA
        Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents.
        Am J Epidemiol. 1995; 142: 202-211
        • Smalley WE
        • Ray WA
        • Daugherty JR
        • Griffin MR
        Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons.
        Am J Epidemiol. 1995; 141: 539-545
        • Kaufman DW
        • Kelly JP
        • Jurgelon JM
        • et al.
        Drugs in the aetiology of agranulocytosis and aplastic anaemia.
        Eur J Haematol. 1996; 60 (Suppl): 23-30
        • Hwang SJ
        • Wu JC
        • Lee CN
        • et al.
        A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B.
        J Gastroenterol Hepatol. 1997; 12: 87-91
        • Hennessy S
        • Strom BL
        • Berlin JA
        • Brennan PJ
        Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis.
        J Gen Intern Med. 1995; 10: 380-386
        • Walker AM
        • Funch D
        • Dreyer NA
        • et al.
        Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis.
        Arthritis Rheum. 1993; 36: 329-335
        • Brown NJ
        • Ray WA
        • Snowden M
        • Griffin MR
        Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.
        Clin Pharmacol Ther. 1996; 60: 8-13
        • Kim WR
        • Poterucha JJ
        • Hermans JE
        • et al.
        Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.
        Ann Intern Med. 1997; 127: 866-874
        • Wasley MA
        • McNagny SE
        • Phillips VL
        • Ahluwalia JS
        The cost-effectiveness of the nicotine transdermal patch for smoking cessation.
        Prev Med. 1997; 26: 264-270
        • Croghan IT
        • Offord KP
        • Evans RW
        • et al.
        Cost-effectiveness of treating nicotine dependence: The Mayo Clinic experience.
        Mayo Clin Proc. 1997; 72: 917-924
        • Scharfstein JA
        • Paltiel AD
        • Freedberg KA
        The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients.
        Med Decis Mak. 1997; 17: 373-381
        • Soumerai SB
        • McLaughlin TJ
        • Spiegelman D
        • et al.
        Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.
        JAMA. 1997; 277: 115-121
        • Guadagnoli E
        • Shapiro C
        • Gurwitz JH
        • et al.
        Age-related patterns of care: Evidence against ageism in the treatment of earlystage breast cancer.
        J Clin Oncol. 1997; 15: 2338-2344
        • McBride JE
        • Pater JL
        • Dorland JL
        • Lam YM
        Extent and variation of omeprazole prescribing in an elderly population of Ontario.
        Ann Pharmacother. 1997; 31: 411-416
        • Last JM
        3rd ed. Dictionary of Epidemiology. Oxford University Press, New York1995
        • Hennekens CH
        • Buring JE
        Epidemiology in Medicine. Little, Brown and Co, Boston1987
        • Rothman KJ
        • Greenland S
        2nd ed. Modern Epidemiology. Lippincott-Raven Publishers, Philadelphia1998
        • Gordis L
        Epidemiology. W.B. Saunders Company, Philadelphia1996
        • McMahon B
        • Trichopoulos D
        2nd ed. Epidemiology: Principles & Methods. Little, Brown and Co, Boston1996
        • Hartzema AG
        • Porta MS
        • Tilson HH
        2nd ed. Pharmacoepidemiology: An Introduction. Harvey Whitney Books Company, Cincinnati1991
      3. Strom BL 2nd ed. Pharmacoepidemiology. John Wiley & Sons, Chichester1994
        • Greenland S
        • Thomas DC
        On the need for the rare disease assumption in case-control studies.
        Am J Epidemiol. 1982; 116: 547-553
        • Miettinen OS
        Estimability and estimation in case-referent studies.
        Am J Epidemiol. 1976; 103: 226-235
        • Members of the ASCPT Pharmacoepidemiology Section
        Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes.
        Clin Pharmacol Ther. 1990; 48: 598